Product Name: VE-822 Request VE-822
Price of VE-822
please inquire via firstname.lastname@example.org
or Fax: 1-201-884-1288
VE-822 is an potent ATR inhibitor. VE-822 inhibited ATR in vitro and in vivo. VE-822 decreased maintenance of cell-cycle checkpoints, increased persistent DNA damage and decreased homologous recombination in irradiated cancer cells. VE-822 decreased survival of pancreatic cancer cells but not normal cells in response to XRT or gemcitabine. VE-822 markedly prolonged growth delay of pancreatic cancer xenografts after XRT and gemcitabine-based chemoradiation without augmenting normal cell or tissue toxicity. These findings support ATR inhibition as a promising new approach to improve the therapeutic ration of radiochemotherapy for patients with PDAC.
Solubility:Soluble in DMSO
Storage Conditions: 2ºC to 8 ºC, or -20ºC for 3 years.